Early age at onset is generally considered an indicator of genetic susceptibility to breast cancer. To address both the proportion of early-onset breast cancer associated with BRCA-1 or BRCA-2 germline mutation and the contribution of germline mutations to the clinical features and outcome of these tumors, we analyzed molecular status and clinical variables of a population-based sample of 66 Italian women diagnosed with breast cancer before the age of 40 who were unselected for family history. BRCA mutations were screened by automated sequencing of the entire BRCA-1 and BRCA-2 coding regions and splice junctions. Twenty-eight late-onset (over 45 years), sporadic, breast cancers were designated as "control group" for comparisons with early-onset cases. BRCA mutations (10 BRCA-1 and 6 BRCA-2) were detected in 15 (22.7%) out of 66 tested patients. The combination of ER, PR, HER-2/neu negativity and p53 positivity was significantly more frequent in BRCA-1 positive tumors than in BRCA-2 positive and non-BRCA tumors (P=0.03). Taken collectively, BRCA-positive tumors correlated with high histologic grade and ER negativity compared with non-BRCA and sporadic tumors (P=0.05 and 0.003, respectively). There were no significant differences between BRCA-associated breast cancers (BABC) and non-BABC in relapse-free, event-free, and overall survival. Our data confirm that the combination of age at onset and tumor phenotype can provide an efficient model for identifying individuals with a high probability of carrying BRCA mutations and support the hypothesis that breast cancer in BRCA carriers is qualitatively distinct from other early-onset breast cancers and from late-onset, sporadic, breast carcinomas. Further studies on incident cases are necessary to define the independent prognostic significance of germline BRCA mutations.

BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study / Musolino, A; Bella, Ma; Bortesi, B; Michiara, M; Naldi, N; Zanelli, P; Capelletti, M; Pezzuolo, D; Camisa, R; Savi, Mario; Neri, Tauro Maria; Ardizzoni, A.. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - Epub ahead of print:(2007), pp. 280-292. [10.1016/j.breast.2006.12.003]

BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study.

MUSOLINO A;SAVI, Mario;NERI, Tauro Maria;
2007-01-01

Abstract

Early age at onset is generally considered an indicator of genetic susceptibility to breast cancer. To address both the proportion of early-onset breast cancer associated with BRCA-1 or BRCA-2 germline mutation and the contribution of germline mutations to the clinical features and outcome of these tumors, we analyzed molecular status and clinical variables of a population-based sample of 66 Italian women diagnosed with breast cancer before the age of 40 who were unselected for family history. BRCA mutations were screened by automated sequencing of the entire BRCA-1 and BRCA-2 coding regions and splice junctions. Twenty-eight late-onset (over 45 years), sporadic, breast cancers were designated as "control group" for comparisons with early-onset cases. BRCA mutations (10 BRCA-1 and 6 BRCA-2) were detected in 15 (22.7%) out of 66 tested patients. The combination of ER, PR, HER-2/neu negativity and p53 positivity was significantly more frequent in BRCA-1 positive tumors than in BRCA-2 positive and non-BRCA tumors (P=0.03). Taken collectively, BRCA-positive tumors correlated with high histologic grade and ER negativity compared with non-BRCA and sporadic tumors (P=0.05 and 0.003, respectively). There were no significant differences between BRCA-associated breast cancers (BABC) and non-BABC in relapse-free, event-free, and overall survival. Our data confirm that the combination of age at onset and tumor phenotype can provide an efficient model for identifying individuals with a high probability of carrying BRCA mutations and support the hypothesis that breast cancer in BRCA carriers is qualitatively distinct from other early-onset breast cancers and from late-onset, sporadic, breast carcinomas. Further studies on incident cases are necessary to define the independent prognostic significance of germline BRCA mutations.
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study / Musolino, A; Bella, Ma; Bortesi, B; Michiara, M; Naldi, N; Zanelli, P; Capelletti, M; Pezzuolo, D; Camisa, R; Savi, Mario; Neri, Tauro Maria; Ardizzoni, A.. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - Epub ahead of print:(2007), pp. 280-292. [10.1016/j.breast.2006.12.003]
File in questo prodotto:
File Dimensione Formato  
BRCA mutations.pdf

non disponibili

Tipologia: Abstract
Licenza: Creative commons
Dimensione 31.62 kB
Formato Adobe PDF
31.62 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer A population-based study..pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 203.88 kB
Formato Adobe PDF
203.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/1629553
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact